
CVS Chooses Harvoni Over Viekira Pak
While Abbvie and Express Scripts announced their deal on Viekira Pak, which was approved in late December to treat hepatitis C, CVS/Caremark today announced that several of it's plans would provide exclusive coverage to Gilead's Sovaldi/Harvoni.
Gilead Sciences' (
Gilead shares spiked on the news Monday, driving up the entire biotech sector. Last month, shares of Gilead swooned after Express Scripts (
"CVS/Caremark has completed a thorough evaluation of the existing and new hepatitis C therapies that are now available in the marketplace," Chris Cramer, a spokeswoman for CVS Health, said in an email statement. The news was first reported by Dow Jones. "As a result of that evaluation, effective January 7, 2015, Harvoni and Sovaldi-manufactured by Gilead Sciences Inc.-will be exclusive on the CVS/Caremark Standard Commercial, Exchange (Marketplace), Medicare Part D and Medicaid formularies. "
Read the complete article on Yahoo!:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.